Disease progression and fatal outcomes in HIV-infected patients during interruption of antiretroviral treatment

Journal of Infectious Diseases

Volumn 197, Issue 5, 2008, Pages 775-

  Cooper, David A ^a   Emery, Sean ^a   Cordery, Damien V ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DISEASE COURSE; FATALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-RETROVIRAL AGENTS; CARDIOVASCULAR DISEASES; CD4 LYMPHOCYTE COUNT; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; RESEARCH DESIGN; SURVIVAL ANALYSIS;

EID: 40549097357     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/527399     Document Type: Letter

References (4)

1. Skiest DJ, Su Z, Havlir DV, et al. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170. J Infect Dis 2007; 195:1426-36.
2. + cell count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-96.
3. Ananworanich J, Gayet-Ageron A, Le Braz M, et al. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet 2006; 368:459-65.
4. Danel C, Moh R, Minga A, et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet 2006; 367:1981-9.